

# Dermabond®

The success of nearly every surgical procedure relies on strong, dependable wound closure.

## Don't compromise –

choose the only topical skin adhesive (TSA) that has been tried, tested, and trusted for nearly 20 years.



## The Innovator

DERMABOND ADVANCED® Topical Skin Adhesive is trusted by more surgeons than any other brand.<sup>1\*</sup>

Although a host of competitors have emerged since DERMABOND® Topical Skin Adhesive helped establish the TSA category in 1998, they haven't been able to match the **innovation**, **efficacy**, and **evidence** behind the market leader.

## The Others

- LiquiBand® Exceed™ Topical Skin Adhesive • Skin Affix™ Topical Skin Adhesive
- SwiftSet™ Topical Skin Adhesive • SurgiSeal® Topical Skin Adhesive
- Derma+Flex® QS™ High Viscosity Tissue Adhesive • Exofin® High Viscosity Tissue Adhesive
- Histoacryl® Topical Skin Adhesive

**ETHICON**  
PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

Shaping  
the future  
of surgery

\*Market-leading claim based on US unit market share data as of September 2016.  
The third party trademarks used herein are trademarks of their respective owners.

## The Innovation

Medical device innovation begins with an idea for improving patient care, and then requires a massive commitment to research and development to make it a reality. In 1998, DERMABOND® Topical Skin Adhesive was introduced to the market, a breakthrough that transformed surgical wound closure.




**SUSTAINED INNOVATION HAS GIVEN RISE TO THE DERMABOND® PORTFOLIO,  
A DIVERSE FAMILY OF SKIN CLOSURE SOLUTIONS FOR A WIDE VARIETY OF CLINICAL NEEDS**



## The Efficacy

DERMABOND ADVANCED Adhesive is more than just a 2-octyl monomer, and every component is essential to the benefits it provides. This efficacy is enabled by Ethicon's proven ability to consistently manufacture millions of units each year while ensuring customers receive a product that meets strict quality guidelines every time.



**Precisely balanced formula provides strong, flexible skin closure plus microbial barrier protection<sup>3,5</sup>**

### TSA's: More than just a monomer

Several competitors have claimed similar benefits just because they share the same 2-octyl monomer, and some have even used studies of DERMABOND Adhesive to support their efficacy claims.<sup>6-8</sup> However, **no competitor has the same formula as DERMABOND ADVANCED Adhesive**, which means they cannot be expected to perform the same.

## Advanced Applicator


The adhesive is only half of the story. By harnessing nearly two decades of TSA expertise, every feature of the 4th generation DERMABOND ADVANCED® Topical Skin Adhesive applicator is designed to optimize surgeon experience and enhance product delivery.



## The Evidence

Ultimately, product efficacy can only be demonstrated through clinical trials and real-world patient studies. When it's time for wound closure, reach for DERMABOND ADVANCED Adhesive - the product supported by far more clinical data than any competitor.<sup>1,9,10†‡§</sup>

DERMABOND ADVANCED Adhesive is supported by substantially more randomized controlled trials (RCTs) than the top 6 competitors combined.<sup>1,9,10†‡§</sup>



Large retrospective analyses support the clinical and economic benefits of DERMABOND ADVANCED Adhesive.

### LENGTH OF STAY

**9 days** with DERMABOND Adhesive

**13 days** without DERMABOND Adhesive

In a retrospective study of 1,360 patients in CABG surgery, postoperative hospital stay was **reduced from 13 days to 9 days** when DERMABOND ADVANCED Adhesive was used in addition to conventional sutures<sup>11</sup>

### TOTAL C-SECTION HOSPITALIZATION COSTS

**\$5,594** Staples

**\$5,572** Sutures

**\$500** reduction

**\$5,010** DERMABOND Adhesive

In a retrospective database study of 155,557 C-sections, **hospitalization costs were \$500 lower** for the DERMABOND ADVANCED Adhesive skin closure group vs. staples or sutures alone<sup>12¶</sup>

\*Compared to DERMABOND® Topical Skin Adhesive.

†DERMABOND ADVANCED Adhesive tests equivalent or superior to DERMABOND Adhesive in head-to-head testing for microbial barrier, wound-bursting strength, tensile strength, flexibility, durability, viscosity, drying time, water vapor transmission rate, water resistance, and physician satisfaction.

‡Based on published literature in PubMed as of March 7, 2017, using only RCTs that evaluated the use of the product in a manner consistent with intended indication.

§Top 6 US competitors include LiquiBand®, Skin Affix™, SwiftSet™, SurgiSeal®, Derma+Flex® QS™, and Histoacryl®.

¶Premier Perspective™ Comparative Database.

Wound closure is key  
to a great surgical outcome.

**Don't settle for less** than the innovation,  
efficacy, and evidence behind  
DERMABOND ADVANCED®  
Topical Skin Adhesive.

For complete indications, contraindications,  
warnings, precautions, and adverse reactions,  
please reference full package insert.

**References:** **1.** Ethicon US Market Share Report, October 2016. **2.** DERMABOND ADVANCED® Topical Skin Adhesive, Instructions for Use, Somerville, NJ; Ethicon, Inc. **3.** Singer AJ, Perry LC, Allen Jr. RL. In vivo study of wound bursting strength and compliance of topical skin adhesives. *Acad Emerg Med.* 2008;15(12):1290-94. **4.** Singer AJ, Perry L. A Comparative Study of the Surgically Relevant Mechanical Characteristics of the Topical Skin Adhesives. *Acad Emerg Med.* 2012;19:1281-86. **5.** Bhende S, Rothenburger S, Spangler DJ, Dito M. In vitro assessment of microbial barrier properties of DERMABOND® Topical Skin Adhesive. *Surg Infect (Larchmt).* 2002;3:251-257. **6.** Singer AJ, Zimmerman T, Rooney J, et al. Comparison of wound-bursting strengths and surface characteristics of FDA-approved tissue adhesives for skin closure. *J Adhesion Sci Technol.* 2004;18(1):19-27. **7.** SurgiSeal® Topical Skin Adhesive Brochure. Accessed January 18, 2017. **8.** Exofin® High Viscosity Tissue Adhesive Brochure, Chemence Medical, Inc. Accessed January 18, 2017. **9.** Dermabond RCT List, Jan 2017. **10.** DBA-32711-8/13, DERMABOND Evidence Summary. **11.** Souza EC, Fitaroni RB, Januzelli DM, et al. Use of 2-octyl cyanoacrylate for skin closure of sternal incisions in cardiac surgery: observations of microbial barrier effects. *Curr Med Res Opin.* 2008;24(1):151-155. **12.** Murrmann SG, Markowitz JS, Gutterman EM, Magee G. Health and economic outcomes after OB-GYN surgery: a comparison of skin closure techniques. Poster presentation at 2008 Annual Clinical Meeting of The American College of Obstetricians and Gynecologists; May 3-7, 2008; New Orleans, LA.